Back to News
May 14, 2026 8:30 AM

CapeHaven Completes First Close of Funding and Initiates Operations to Encourage Yale's Biotech Spinouts

NEW HAVEN, Conn., May 14, 2026 (GLOBE NEWSWIRE) -- CapeHaven, LLC, a New Haven-based biotech venture creation platform, announced today that it has completed a first close on the path toward its target of $10 million. This initial tranche of funding was sourced from both individual and institutional investors.

CapeHaven is focused on identifying high-potential academic discoveries, primarily within the Yale ecosystem, and advancing them through the scientific, operational, and strategic milestones required to build fundable biotechnology companies.

This funding supports the following initiatives:

Expansion of the CapeHaven scientific and venture creation team

Evaluation and advancement of early-stage therapeutic opportunities emerging from academic laboratories

Launch of Brainstorm Cancer Therapeutics, an oncology-focused discovery company

Founded by biotech veterans Ranjit Bindra, M.D., Ph.D, Seth Herzon, Ph.D., Kevin Rakin, and Mike Dillon, Ph.D., CapeHaven is designed to bridge the gap between academic discovery and company formation. Bindra is the ...